Related Experiment Video

Updated: Jun 4, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism

Sarah Garrido-Urbani1, Stephane Jemelin, Christine Deffert

  • 1Department of Pathology and Immunology, Centre Médical Universitaire, University of Geneva, Geneva, Switzerland.

Plos One
|February 18, 2011
PubMed

Insights

Vascular NOX1 (NADPH oxidase 1) is crucial for new blood vessel formation (angiogenesis). Inhibiting NOX1 reduces endothelial cell function and tumor growth, highlighting NOX1 as a therapeutic target.

Area of Science:

  • Vascular biology
  • Cell signaling
  • Oncology

Background:

  • Reactive oxygen species (ROS) regulate key endothelial cell functions, including migration, proliferation, and survival, which are essential for angiogenesis.
  • NADPH oxidase (NOX) enzymes generate ROS in the vasculature, providing distinct signaling cues via differential localization and activation.

Purpose of the Study:

  • To investigate the role of specific NOX isoforms in angiogenesis.
  • To explore NOX1 as a potential therapeutic target for anti-angiogenic therapies.

Main Methods:

  • Comparative analysis of angiogenesis in mice deficient in different NOX isoforms (NOX1, NOX2, NOX4).
  • Assessment of NOX1 expression and activity in endothelial cells upon angiogenic stimulation.
  • Evaluation of NOX1 silencing effects on endothelial cell migration and tube-like structure formation.
  • In vivo studies using a NOX-specific inhibitor to assess its impact on angiogenesis and tumor growth.

Main Results:

  • Mice lacking NOX1 exhibited impaired angiogenesis, while NOX2 or NOX4 deficiency did not.
  • NOX1 expression and activity were upregulated in endothelial cells during angiogenic stimulation.
  • Silencing NOX1 inhibited endothelial cell migration and tube formation by downregulating PPARα, a regulator of NF-κB.
  • A novel NOX-specific inhibitor reduced angiogenesis and tumor growth in a PPARα-dependent manner.

Conclusions:

  • Vascular NOX1 is a critical mediator of angiogenesis.
  • NOX1 represents an attractive molecular target for developing anti-angiogenic therapies.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: